1. IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN. (June 2017) Authors: Hiddemann, W.; Barbui, A.M.; Canales Albendea, M.A.; Cannell, P.K.; Collins, G.P.; Dürig, J.; Forstpointner, R.; Herold, M.; Hertzberg, M.; Klanova, M.; Radford, J.A.; Tobinai, K.; Burciu, A.; Fingerle‐Rowson, G.R.; Nielsen, T.; Wolbers, M.; Marcus, R. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R‐CHOP, R‐MCP, R‐FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO. (June 2017) Authors: Hoster, E.; Unterhalt, M.; Hänel, M.; Prange‐Krex, G.; Forstpointner, R.; Florschütz, A.; Graeven, U.; Frickhofen, N.; Wulf, G.; Lengfelder, E.; Lerchenmüller, C.; Schlag, R.; Dierlamm, J.; Fischer Von Weikersthal, L.; Ahmed, A.; Harich, H.; Rosenwald, A.; Klapper, W.; Dreyling, M.; Hiddemann, W. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗